XenoPort to continue development of XP23829 after Phase 1 results


XenoPort announced the preliminary results from two Phase 1 studies with XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. Based on the favorable preliminary results from these studies, XenoPort intends to continue to advance the development of XP23829 as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.

View Comments (0)